Trial Profile

Persistence with Etanercept or other TNFi monotherapy among rheumatoid arthritis patients who achieved remission or low disease activity on combination TNFi+csDMARD therapy: data from CORRONA registry

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 01 Dec 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Adalimumab (Primary) ; Certolizumab pegol (Primary) ; Etanercept (Primary) ; Golimumab (Primary) ; Infliximab (Primary) ; Hydroxychloroquine; Leflunomide; Methotrexate; Sulfasalazine
Indications Rheumatoid arthritis
Focus Therapeutic Use

24 Oct 2018 Results presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
14 Jul 2018 New trial record
16 Jun 2018 Results presented at the 19th Annual Congress of the European League Against Rheumatism

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com